Cargando…

Is IL-6 the Right Target in COVID-19 Severe Pneumonia?

Detalles Bibliográficos
Autores principales:	Blot, Mathieu, Bourredjem, Abderrahmane, Binquet, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781133/ https://www.ncbi.nlm.nih.gov/pubmed/32955921 http://dx.doi.org/10.1164/rccm.202007-2924LE

Ejemplares similares

Are adipokines the missing link between obesity, immune response, and outcomes in severe COVID-19?
por: Blot, Mathieu, et al.
Publicado: (2021)

Specific Features of the Coagulopathy Signature in Severe COVID-19 Pneumonia
por: Blot, Mathieu, et al.
Publicado: (2021)

Addition of daptomycin for the treatment of pneumococcal meningitis: protocol for the AddaMAP study
por: Chavanet, Pascal, et al.
Publicado: (2023)

The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome
por: Blot, Mathieu, et al.
Publicado: (2020)

Correction to: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome
por: Blot, Mathieu, et al.
Publicado: (2021)

High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia
por: Nguyen, Maxime, et al.
Publicado: (2021)

Differential effect on mortality of the timing of initiation of renal replacement therapy according to the criteria used to diagnose acute kidney injury: an IDEAL-ICU substudy
por: Barbar, Saber Davide, et al.
Publicado: (2023)

Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma
por: Sgherza, Nicola, et al.
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Role of IL-6 in Severe Inflammation
por: Inoue, Ken-ichiro, et al.
Publicado: (2021)

Systemic IL-6 and Severe Asthma
por: Lipworth, Brian, et al.
Publicado: (2020)

COVID-19: Clean up on IL-6
por: Hedrick, Tanner L., et al.
Publicado: (2020)

Severe Hypoxemia in Early COVID-19 Pneumonia
por: Bhatia, Pradeep, et al.
Publicado: (2020)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19
por: Garbers, Christoph, et al.
Publicado: (2021)

Aspergillus colonisation in severe community-acquired pneumonia: not just a mere colonisation
por: Pineau, Valentin, et al.
Publicado: (2023)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 – Authors' reply
por: Bovijn, Jonas, et al.
Publicado: (2021)

Provision of holistic care after severe COVID-19 pneumonia
por: McPeake, Joanne, et al.
Publicado: (2021)

High-Dose Prophylactic Anticoagulation in Severe COVID-19 Pneumonia
por: Nadeem, Rashid, et al.
Publicado: (2021)

Is the Pelvis-Thorax Coordination a Valuable Outcome Instrument to Assess Patients With Hip Osteoarthritis?
por: Moissenet, Florent, et al.
Publicado: (2020)

Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia
por: Elabbadi, Alexandre, et al.
Publicado: (2021)

Delayed diagnosis of pneumonia in the emergency department: factors associated and prognosis
por: Bouam, Maria, et al.
Publicado: (2023)

Early Reversal of Right Ventricular Dysfunction after Venovenous Extracorporeal Membrane Oxygenation in Patients with COVID-19 Pneumonia
por: Levy, David, et al.
Publicado: (2022)

Provision of holistic care after severe COVID-19 pneumonia – Authors' reply
por: D'Cruz, Rebecca F, et al.
Publicado: (2021)

Evaluating rates of ventilator-associated pneumonia: Consider patient, organizational & educational risk factors
por: Koulenti, Despoina, et al.
Publicado: (2017)

Association between the retinal vascular network and retinal nerve fiber layer in the elderly: The Montrachet study
por: Arnould, Louis, et al.
Publicado: (2020)

Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19
por: Bovijn, Jonas, et al.
Publicado: (2020)

Severe COVID-19 pneumonia in patients with rheumatoid arthritis under B-cell depletion therapy
por: Wang, Chrong-Reen, et al.
Publicado: (2023)

COVID-19 ARDS: getting ventilation right
por: Pérez-Fernández, Xosé L, et al.
Publicado: (2022)

Association between the retinal vascular network with Singapore "I" Vessel Assessment (SIVA) software, cardiovascular history and risk factors in the elderly: The Montrachet study, population-based study
por: Arnould, Louis, et al.
Publicado: (2018)

Downregulated miR-451a as a feature of the plasma cfRNA landscape reveals regulatory networks of IL-6/IL-6R-associated cytokine storms in COVID-19 patients
por: Yang, Penghui, et al.
Publicado: (2021)

Microvascular Shunts in COVID-19 Pneumonia
por: Bush, Douglas, et al.
Publicado: (2022)

IL-6 modulation for COVID-19: the right patients at the right time?
por: Ascierto, Paolo Antonio, et al.
Publicado: (2021)

Inhibiting C5 in patients with severe COVID-19—the incorrect target?
por: Lim, Endry H T, et al.
Publicado: (2023)

Prediction of Cardiovascular Parameters With Supervised Machine Learning From Singapore “I” Vessel Assessment and OCT-Angiography: A Pilot Study
por: Arnould, Louis, et al.
Publicado: (2021)

COVID-19 and complicated bacterial pneumonia in children
por: Kaddour, Mohamad, et al.
Publicado: (2021)

Trial participants' rights after authorisation of COVID-19 vaccines
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

COVID-19 May Be Exacerbated by Right-to-Left Interatrial Shunt
por: Rajendram, Rajkumar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dvslc1v4ndftggjt2vnieajo12